ArticleMolecular therapy. Oncology2026
Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Progress in Virotherapy: Application and Future Prospects in Head and Neck Cancer.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic virotherapy (OV) has emerged as a promising cancer treatment strategy, utilizing viruses to selectively infect and destroy tumor cells while simultaneously stimulating anti-tumor immunity. OV has also been shown to modulate the tumor immune microenvironment, enhancing the efficacy of immunotherapy. Despite the recent regulatory approvals of oncolytic viruses such as T-VEC (JS1/34.5-/47-/GM-CSF), Oncorine (H101), and Teserpaturev (G47Δ), the clinical impact of OV remains limited by its reliance on intratumoral administration. Systemic delivery is essential for effectively treating metastatic and inaccessible tumors but is hindered by two major challenges: rapid clearance by the mononuclear phagocyte system (MPS) and neutralization by antiviral antibodies. To overcome these barriers, we developed FusOn-SD, an enhanced version of FusOn-H2 engineered for systemic delivery. Our strategy integrates both genetic and adaptive modifications: (1) incorporating the extracellular domain (ECD) of CD47 to evade MPS-mediated clearance and (2) serially passaging the virus in immune sera to enhance resistance to neutralizing antibodies. Preclinical studies demonstrate that FusOn-SD efficiently reaches tumor sites following systemic administration, exhibiting enhanced immune evasion and oncolytic potency. These findings position FusOn-SD as a promising candidate for advancing OV beyond localized injections, with the potential to transform virotherapy into a viable treatment for metastatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.